BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hatzipantelis CJ, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, Stewart GD, Langmead CJ. Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia. ACS Pharmacol Transl Sci 2020;3:1042-62. [PMID: 33344888 DOI: 10.1021/acsptsci.0c00117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Veselinović T, Neuner I. Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. CNS Drugs 2022. [PMID: 35831706 DOI: 10.1007/s40263-022-00935-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Raines R, Mcknight I, White H, Legg K, Lee C, Li W, Lee PHU, Shim JW. Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs. Biomedicines 2022;10:594. [DOI: 10.3390/biomedicines10030594] [Reference Citation Analysis]
3 Martínez AL, Brea J, Rico S, de Los Frailes MT, Loza MI. Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments. Int J Mol Sci 2021;22:9905. [PMID: 34576069 DOI: 10.3390/ijms22189905] [Reference Citation Analysis]
4 Lim LW, Aquili L. GABA Supplementation Negatively Affects Cognitive Flexibility Independent of Tyrosine. J Clin Med 2021;10:1807. [PMID: 33919136 DOI: 10.3390/jcm10091807] [Reference Citation Analysis]